Where innovative Medical Go-To-Market Success is the rule! 

Want to Learn or See More? Click here

Synergistic Marketing, founded in 1990 by Mark Lutvak, is a successful, growing and profitable sales and marketing contracting firm and consultancy. We are dedicated to serving Small Emerging businesses that own or possess Medical Technology or Medical Device IP. We support our clients with a go-to-market strategy that takes advantage of our extensive network of medical industry companies as well as our extensive list of contacts who are our Corporate Partners.

Want to Learn or See More? Click here

 

Medical Technology and Device News Title

  • January 22, 2015:

    Medtronic, Inc. has announced MiniMed 640G the system both automatically suspends insulin delivery when sensor glucose levels are predicted to approach a low limit and resume insulin delivery once sensor glucose levels recover. “With the MiniMed 640G, we're thrilled to deliver a new system that meets these needs and marks the third significant milestone to creating and commercializing the world's first artificial pancreas," said Alejandro Galindo, vice president and general manager of the Intensive Insulin Management business at Medtronic. Full Story

  • January 20, 2015:

    Researchers from North Carolina State University have developed a new, wearable sensor that uses silver nanowires to monitor electrophysiological signals, such as electrocardiography (EKG) or electromyography (EMG). The new sensor is as accurate as the "wet electrode" sensors used in hospitals, but can be used for long-term monitoring and is more accurate than existing sensors when a patient is moving. Long-term monitoring of electrophysiological signals can be used to track patient health or assist in medical research, and may also be used in the development of new powered prosthetics that respond to a patient's muscular signals. l Story

  • January 14, 2015:

    Chung-Yuan Hu, M.P.H., Ph.D., of the University of Texas MD Anderson Center, Houston, and coauthors examined patterns of primary tumor resection (PTR) and survival in stage IV CRC in the United States. They found that the annual rate of primary tumor removal for advanced stage IV colorectal cancer (CRC) has decreased since 1988 and the trend toward nonsurgical management of the disease noted in 2001 coincides with the availability of newer chemotherapy and biologic treatments. Full Story

  • January 14, 2015:

    Stanford's Vijay Pande has partnered with Sony to create a powerful distributed network for studying protein behavior using smartphones. Proteins are produced as linear ribbons of molecules, and then snarl up like a ball of yarn, a process known as "folding." If a mutation or other malfunction shifts a few pieces during the folding process and leaves them slightly out of place, the protein's function will be impaired, it potentially won't work at all or, worse, it will work in a way that is harmful to the organism. One of the best ways to study protein configurations is to predict the folding process using computers. By using smartphones while they are otherwise idle in a combined network, Pande can harness their power to provide critical insight into the biology of diseases and lead the way to potential new treatments.Full Story

  • January 12, 2015:

    Scientists from Case Western Reserve University's School of Medicine have discovered a potential treatment that may steer cancer cells toward their own destruction by suppressing the UbcH7 process. The study focused on a particular gene that was found to influence levels of a tumor-fighting protein called 53BP1, the heightened presence of which makes cancer cells more vulnerable to existing forms of treatment.Full Story

  • January 6, 2015:

    In 2014, prostate cancer was the leading cause of newly diagnosed cancers in men and the second leading cause of cancer death in men.
    Writing in the January 6, 2015 issue of the journal Prostate Cancer and Prostatic Disease, a team of scientists and physicians from the University of California, San Diego School of Medicine, with counterparts at University of California, Los Angeles, describe a novel imaging technique that measurably improves upon current prostate imaging. The new approach is called restriction spectrum imaging-MRI or RSI-MRI. It corrects for magnetic field distortions and focuses upon water diffusion within tumor cells. By doing both, the ability of imaging to accurately plot a tumor's location is increased and there is a more refined sense of the tumor's extent, said Nathan White, PhD, assistant project scientist at UC San Diego, study co-author and co-inventor of the RSI-MRI technique.Full Story